Fresenius SE Other Non-Current Liabilities 2016-2024 | FSNUY
Fresenius SE other non-current liabilities from 2016 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Fresenius SE other non-current liabilities for the quarter ending September 30, 2024 were $1.317B, a 32.38% decline year-over-year.
- Fresenius SE other non-current liabilities for 2023 were $2.01B, a 37.33% decline from 2022.
- Fresenius SE other non-current liabilities for 2022 were $3.207B, a 40.75% increase from 2021.
- Fresenius SE other non-current liabilities for 2021 were $2.279B, a 9% decline from 2020.
Fresenius SE Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$2,010 |
| 2022 |
$3,207 |
| 2021 |
$2,279 |
| 2020 |
$2,504 |
| 2019 |
$2,076 |
| 2018 |
$2,198 |
| 2017 |
$2,636 |
| 2016 |
$1,578 |
| 2015 |
$1,306 |
Fresenius SE Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-09-30 |
$1,317 |
| 2024-06-30 |
$1,222 |
| 2024-03-31 |
$2,031 |
| 2023-12-31 |
$2,010 |
| 2023-09-30 |
$1,948 |
| 2023-06-30 |
$3,225 |
| 2023-03-31 |
$261 |
| 2022-12-31 |
$3,207 |
| 2022-09-30 |
$3,083 |
| 2022-06-30 |
$2,315 |
| 2022-03-31 |
$1,865 |
| 2021-12-31 |
$2,279 |
| 2021-09-30 |
$4,193 |
| 2021-06-30 |
$347 |
| 2021-03-31 |
$2,498 |
| 2020-12-31 |
$2,504 |
| 2020-09-30 |
$2,259 |
| 2020-06-30 |
$2,113 |
| 2020-03-31 |
$2,023 |
| 2019-12-31 |
$2,076 |
| 2019-09-30 |
$2,048 |
| 2019-06-30 |
$2,127 |
| 2019-03-31 |
$2,113 |
| 2018-12-31 |
$2,198 |
| 2018-09-30 |
$2,361 |
| 2018-06-30 |
$2,608 |
| 2018-03-31 |
$2,659 |
| 2017-12-31 |
$2,636 |
| 2017-09-30 |
$2,788 |
| 2017-06-30 |
$2,084 |
| 2017-03-31 |
$2,120 |
| 2016-12-31 |
$1,578 |
| 2016-09-30 |
$1,371 |
| 2016-06-30 |
$1,358 |
| 2016-03-31 |
$1,272 |
| 2015-12-31 |
$2,503 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$21.804B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
